Skip to main content
. 2021 Jan 29;23:43. doi: 10.1186/s13075-021-02428-8

Table 2.

Structural lesion change according to sex in patients with axial spondyloarthritis, baseline to week 104

Structural lesion Study cohort Sex Lesion decreased n/N (%) Lesion increased n/N (%) Net % patients with decrease within study cohort (95% CI) P value for lesion decrease vs increase P value for difference in sex (both studies pooled) P value for difference in study (both sexes pooled) P value for difference in sex (by study) P value for difference in study (by sex)
 Erosion

Etanercept

(EMBARK)

Male 39/105 (37.1) 6/105 (5.7) 31.4% (21.3, 41.6) < 0.001 0.048 0.03 0.02 0.02
Female 7/58 (12.1) 1/58 (1.7) 10.3% (− 3.3, 24.0) 0.14 0.38

Control

(DESIR)

Male 10/45 (22.2) 6/45 (13.3) 8.9% (− 6.6, 24.4) 0.26 0.47
Female 4/31 (12.9) 4/31 (12.9) 0% (− 18.7, 18.7) 1.0
Structural lesion Study cohort Lesion increased n/N (%) Lesion decreased n/N (%) Net % patients with increase within study cohort (95% CI) P value for lesion increase vs decrease P value for difference in sex (both studies pooled) P value for difference in study (both sexes pooled) P value for difference in sex (by study) P value for difference in study (by sex)
 Backfill

Etanercept

(EMBARK)

Male 24/105 (22.9) 1/105 (1.0) 21.9% (14.6, 29.2) < 0.001 0.03 0.50 0.008 0.21
Female 3/58 (5.2) 0/58 (0) 5.2% (− 4.6, 15.0) 0.30 0.88

Control

(DESIR)

Male 8/45 (17.8) 2/45 (4.4) 13.3% (2.2, 24.5) 0.02 0.44
Female 2/31 (6.5) 0/31 (0) 6.5% (− 7.0, 19.9) 0.35
 Fat metaplasia

Etanercept

(EMBARK)

Male 13/105 (12.4) 2/105 (1.9) 10.5% (4.7, 16.2) < 0.001 0.03 0.61 0.07 0.59
Female 1/58 (1.7) 0/58 (0) 1.7% (− 6.0, 9.5) 0.66 0.82

Control

(DESIR)

Male 6/45 (13.3) 0/45 (0) 13.3% (4.6, 22.1) 0.003 0.15
Female 1/31 (3.2) 0/31 (0) 3.2% (− 7.4, 13.8) 0.55
 Ankylosis

Etanercept

(EMBARK)

Male 2/105 (1.9) 1/105 (1.0) 1.0% (− 1.8, 3.7) 0.50 0.24 0.47 0.26 0.62
Female 0/58 (0) 1/58 (1.7) − 1.7% (− 5.5, 2.0) 0.37 0.59

Control

(DESIR)

Male 1/45 (2.2) 0/45 (0) 2.2% (− 2.0, 6.5) 0.31 0.51
Female 0/31 (0) 0/31 (0) 0% (− 5.1, 5.1) 1.0